Skip to Main Content

Key Action Statement Profile: KAS 6A

Aggregate evidence quality Grade B 
Benefits Reduced frequency of AOM attributable to vaccine serotypes. Reduced risk of serious pneumococcal systemic disease. 
Risks, harms, cost Potential vaccine side effects. Cost of vaccine. 
Benefits-harms assessment Preponderance of benefit. 
Value judgments Potential vaccine adverse effects are minimal. 
Intentional vagueness None. 
Role of patient preferences Some parents may choose to refuse the vaccine. 
Exclusions Severe allergic reaction (eg, anaphylaxis) to any component of pneumococcal vaccine or any diphtheria toxoid-containing vaccine. 
Strength Strong Recommendation 
Aggregate evidence quality Grade B 
Benefits Reduced frequency of AOM attributable to vaccine serotypes. Reduced risk of serious pneumococcal systemic disease. 
Risks, harms, cost Potential vaccine side effects. Cost of vaccine. 
Benefits-harms assessment Preponderance of benefit. 
Value judgments Potential vaccine adverse effects are minimal. 
Intentional vagueness None. 
Role of patient preferences Some parents may choose to refuse the vaccine. 
Exclusions Severe allergic reaction (eg, anaphylaxis) to any component of pneumococcal vaccine or any diphtheria toxoid-containing vaccine. 
Strength Strong Recommendation 
Close Modal

or Create an Account

Close Modal
Close Modal